ArticleFrontiers in oncology2025
SiameseNet based on multiple instance learning for accurate identification of the histological grade of ICC tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: After hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer. Timely and accurate identification of ICC histological grade is critical for guiding clinical diagnosis and treatment planning. Method: We proposed a dual-branch deep neural network (SiameseNet) based on multiple-instance learning and cross-attention mechanisms to address tumor heterogeneity in ICC histological grade prediction. The study included 424 ICC patients (381 in training, 43 in testing). The model integrated imaging data from two modalities through cross-attention, optimizing feature representation for grade classification. Results: In the testing cohort, the model achieved an accuracy of 86.0%, AUC of 86.2%, sensitivity of 84.6%, and specificity of 86.7%, demonstrating robust predictive performance. Conclusion: The proposed framework effectively mitigates performance degradation caused by tumor heterogeneity. Its high accuracy and generalizability suggest potential clinical utility in assisting histopathological assessment and personalized treatment planning for ICC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.